

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

MURRAY & POOLE ENTERPRISES LTD.,

Petitioner,

v.

INSTITUT DE CARDIOLOGIE DE MONTREAL,

Patent Owner.

Case IPR2023-01064

Patent 11,400,063

PATENT OWNER'S CORRECTED EXHIBIT LIST

Pursuant to 37 C.F.R. §§ 42.63(e) and 42.64(b)(2), Patent Owner Institut de Cardiologie de Montréal hereby submits a corrected listing of Patent Owner's exhibits. Exhibits 2001-2016 were filed on October 18, 2023.

Exhibit	Description
2001	Declaration of Hossein Ardehali, M.D.
2002	Australia New Zealand Clinical Trials Registry, The LoDoCo Trial: The effect of low dose colchicine on the natural history of patients with stable coronary artery disease (ACTRN12610000293066) (2014) ("LoDoCo Trial")
2003	Clinicaltrials.gov identifier NCT01327846, <i>Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events) (CANTOS)</i> , https://clinicaltrials.gov/study/NCT01327846?titles=CANTOS&rank=1 (last accessed Oct. 4, 2023) ("CANTOS")
2004	Clinicaltrials.gov identifier NCT02551094, <i>Colchicine Cardiovascular Outcomes Trial (COLCOT)</i> , https://clinicaltrials.gov/study/NCT02551094?titles=COLCOT&rank=1 (last accessed Oct. 4, 2023) ("COLCOT")
2005	M. Imazio et al., <i>Colchicine in addition to conventional therapy for acute pericarditis: results of the Colchicine for acute Pericarditis (COPE) trial</i> , 112 CIRCULATION 2012-2016 (2005) ("Imazio 2005a")
2006	M. Imazio et al., <i>Colchicine as first choice therapy for recurrent pericarditis: results of the CORE (Colchicine for Recurrent pericarditis) trial</i> , 165 ARCH. INTERN. MED. 1987-1991 (2005) ("Imazio 2005b")
2007	M. Imazio et al., <i>Colchicine for recurrent pericarditis (CORP): a randomized trial</i> , 155 ANN. INTERN. MED. 409-414 (2011) ("Imazio 2011")
2008	Maria Isabel Lopes et al., <i>Beneficial effects of colchicine for moderate to severe COVID-19: a randomized double-blinded, placebo-controlled clinical trial</i> , 7 RMD Open 1455 (2021)
2009	J.H. O'Keefe et al., <i>Ineffectiveness of colchicine for the prevention of restenosis after coronary angioplasty</i> , 19 J. AM. COLL. CARDIOL. 1597-1600 (1992) ("O'Keefe")

2010	Terkeltaub et al., <i>High versus low dosing of oral colchicine for early acute gout flare: Twenty-four hour outcome of the first multicenter, randomized, double-blinded, placebo-controlled, parallel-group, dose-comparison colchicine study</i> , 62 ARTHRITIS & RHEUMATOLOGY 1060-1068 (2010)
2011	Declaration of Jean-Claud Tardif, M.D.
2012	COLCOT Site 1004 Research Agreement
2013	COCLLOT Leschke Site Research Agreement
2014	COLCOT Berube Site Research Agreement
2015	COLCOT Fung Site Research Agreement
2016	Funding Approval Letter from Quebec Ministry of Finance
2017	RESERVED

Respectfully submitted,

Date: April 30, 2024

By: /s/ Sailesh Patel
Sailesh K. Patel, Reg. No. 46,982
Lead Counsel for Patent Owner
Institut de Cardiologie de Montréal

CERTIFICATE OF SERVICE

Pursuant to 37 C.F.R. §§ 42.6(e) and 42.105(a), the undersigned certifies that on April 30, 2024, a copy of the foregoing Patent Owner's Corrected Exhibit List were served electronically via e-mail on the following:

Joanna Brougher (jbrougher@biopharmalaw.com)

Thomas Siepmann (tsiepmann@biopharmalaw.com)

Kevin Laurence (klaurence@lpiplaw.com)

Matthew Phillips (mphilips@lpiplaw.com)

Derek Meeker (dmeeker@lpiplaw.com)

Joe Hawkins (jhawkins@lpiplaw.com)

Petitioner has agreed to electronic service.

Dated: April 30, 2024

By: /s/ Matthew Wilkerson
Matthew T. Wilkerson
ARENTFOX SCHIFF LLP